Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials

<table>Results of Forest plots of comparison of CMs plus TACE versus TACE alone on 6-month, 18-month, 24-month, and 36-month survival for HCC patients at middle and late stages. M-H: Mantel-Haenszel estimates; CI: confidence interval; CMs: Chinese medicines; TACE: transcatheter arterial chemoembolization.</table>

Evidence-Based Complementary and Alternative Medicine

fig3

Figure 3

Figure 3: Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials 

Figure 3 | Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials 